SAN

73.27

-0.95%↓

ARGX

675.2

-5.59%↓

SHL.DE

33.55

-2.27%↓

PHIA

21.79

-1.63%↓

FRE

35.27

+0.23%↑

SAN

73.27

-0.95%↓

ARGX

675.2

-5.59%↓

SHL.DE

33.55

-2.27%↓

PHIA

21.79

-1.63%↓

FRE

35.27

+0.23%↑

SAN

73.27

-0.95%↓

ARGX

675.2

-5.59%↓

SHL.DE

33.55

-2.27%↓

PHIA

21.79

-1.63%↓

FRE

35.27

+0.23%↑

SAN

73.27

-0.95%↓

ARGX

675.2

-5.59%↓

SHL.DE

33.55

-2.27%↓

PHIA

21.79

-1.63%↓

FRE

35.27

+0.23%↑

SAN

73.27

-0.95%↓

ARGX

675.2

-5.59%↓

SHL.DE

33.55

-2.27%↓

PHIA

21.79

-1.63%↓

FRE

35.27

+0.23%↑

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Avatud

SektorTervishoid

57.55 -0.26

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

57.35

Max

57.95

Põhinäitajad
By Trading Economics
Sissetulek	-33M 9.5M
Müük	-66M 152M
P/E Sektori keskmine	24.47 49.888
Aktsiakasum	0.185
Kasumimarginaal	6.216
Töötajad	1,950
EBITDA	-45M 18M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+25.92% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	23. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-1.1B 3B
Eelmine avamishind	57.81
Eelmine sulgemishind	57.55

Uudiste sentiment

By Acuity

50%

147 / 344 Pingereas Healthcare

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2026, 20:30 UTC

Tulu

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2. juuni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. juuni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. juuni 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. juuni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. juuni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. juuni 2026, 21:00 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. juuni 2026, 20:46 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:38 UTC

Tulu

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. juuni 2026, 20:21 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:12 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Product Rev $594M

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Adj EPS 85c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Loss $177M >PANW

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

25.92% tõus

12 kuu keskmine prognoos

Keskmine 73.6 EUR 25.92%

Kõrge 83 EUR

Madal 64.2 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

147 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.